FON-2021-0899 Infographic – Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003
figure
posted on 2021-11-16, 11:57 authored by Tae Won Kim, Julien Taieb, Ellen B Gurary, Nati Lerman, Karen Cui, Takayuki YoshinoInfographic: Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003
Funding
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., NJ, USA, and AstraZeneca
History
Usage metrics
Keywords
Licence
Exports
RefWorksRefWorks
BibTeXBibTeX
Ref. managerRef. manager
EndnoteEndnote
DataCiteDataCite
NLMNLM
DCDC